Riskpilot← Back to searchSign inGet full accessGlenmark Pharmaceuticals Nordic AB
ABActiveOrg 5590657085Propellergatan 2Wholesale of pharmaceutical and medical goods · NACE 4646Est. 20167 employees
Revenue 2025
SEK 311,6M
+46% vs 2024
EBITDA margin
4.0%
+209% vs 2024
Equity ratio
14.6%
Financial strength
Net profit 2025
SEK 9,9M
+164% vs 2024
| Revenue | SEK 311,6M | +46% |
| EBITDA | SEK 12,4M | +209% |
| Net profit | SEK 9,9M | +164% |
| Total assets | SEK 224M | +73% |
| Equity | SEK 32,7M | +43% |
| Employees | 7 | — |
Legal name
Glenmark Pharmaceuticals Nordic AB
Org number
5590657085
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
8 juni 2016
Share capital
SEK 50 000
Employees
7 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-03-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Föremålet för bolagets verksamhet är att bedriva produktion, marknadsföring, distribution, export och import av läkemedel och produkter inom läkemedelsbranschen samt därmed förenlig verksamhet.
Address
Propellergatan 2
Email
finance.nordic@lenmarkpharma.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 93 433 | 93 295 | 156 898 | 212 843 | 311 646 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 2 066 | 2 476 | 5 549 | 4 030 | 12 435 |
| Depreciation & amort. | −70 | −29 | −0 | −0 | −0 |
| EBIT | 1 996 | 2 447 | 5 549 | 4 030 | 12 435 |
| Net financials | −18 | −3 | −7 | 6 | 150 |
| Profit before tax | 1 978 | 2 444 | 5 542 | 4 036 | 12 586 |
| Tax | −0 | −0 | −0 | −294 | −2 714 |
| Net profit | 1 978 | 2 444 | 5 542 | 3 742 | 9 872 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 72 204 | 107 472 | 98 182 | 129 807 | 224 014 |
| Equity | 11 147 | 13 592 | 19 134 | 22 875 | 32 747 |
| Long-term debt | 50 193 | 85 002 | 0 | 0 | 0 |
| Short-term debt | 10 864 | 8 878 | 79 049 | 106 932 | 191 267 |
| Total debt | 61 057 | 93 880 | 79 049 | 106 932 | 191 267 |
EBITDA margin
4.0%
This company
15.8%
Market median
-75% vs market
20212025
Equity ratio
14.6%
This company
38.2%
Market median
-62% vs market
20212025
Return on equity
30.1%
This company
18.4%
Market median
+64% vs market
20212025
Net profit margin
3.2%
This company
8.1%
Market median
-60% vs market
20212025
Asset turnover
1.39×
This company
1.12×
Market median
+24% vs market
20212025
Debt / equity
5.84×
This company
0.62×
Market median
-842% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-04-01 – 2025-03-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-04-01 – 2024-03-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-04-01 – 2023-03-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-04-01 – 2022-03-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-04-01 – 2021-03-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
ER Chief Auditor | Chief Auditor | 2022 |
| Former (2) | ||
NJ Authorized Recipient of Service | Authorized Recipient of Service | 2022 – 2022 |
KR Chief Auditor | Chief Auditor | 2024 – 2025 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2022 | |
| Deputy Board Member | 2024 | |
| Former (2) | ||
| Deputy Board Member | 2022 – 2022 | |
| Board of Directors | 2024 – 2025 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Glenmark Pharmaceuticals Nordic AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Emma Rebecka Josefine Iderup | Chief Auditor | 0 companies |
| Nils Jakob Vilhelm Nortoft | Authorized Recipient of Service | 0 companies |
| Kent Robert Axgart Wennerlund | Chief Auditor | 0 companies |
| Achin Gupta | Deputy Board Member | 0 companies |
| Oliver Henry Bourne | Board of Directors | 0 companies |
| Hans Henric Juserius | Board of Directors | 0 companies |
| Alexander Marcus Valdix | Deputy Board Member | 0 companies |